FalconGene's next-generation sequencing (NGS) tests in pharmacogenetics are designed based on complex gene-disease associations and can analyze multiple genes simultaneously. It scans for all relevant variants in coding regions, regulatory sequences and intronic regions. This allows our clients to receive a more accurate and comprehensive diagnosis.
The relationship between some important genes and drugs and the advantages of drug susceptibility testing:
Neurology:
Amisulpride and MC4R Gene Relationship:
A genetic component has been observed in the response to amisulpride treatment. Certain variants in the MC4R gene may contribute to reduced weight gain and metabolic side effects during treatment. This may improve treatment compliance and ultimately increase treatment success.
Relationship between Carbamazepine (CBZ) and EPHX1 Gene:
The effectiveness of anticonvulsant drugs such as carbamazepine has been linked to genetic variations seen in patients. Certain alleles of the EPHX1 gene are associated with lower dose requirements during carbamazepine treatment. This may contribute to the development of personalized dosing strategies and increase the effectiveness of treatment.
Cardiology:
Relationship between YEATS4 Gene and Hydrochlorothiazide (HCTZ):
The effectiveness of diuretics such as hydrochlorothiazide has been linked to genetic variations in patients. Certain variants of the YEATS4 gene have been found in patients who respond better to hydrochlorothiazide treatment. This may increase the drug's effectiveness in controlling hypertension and reduce cardiovascular risks.
Pain Treatment:
Relationship between Aspirin and PTGS1 Gene:
Aspirin is a medication used to treat pain, fever, and inflammation.
A genetic variant associated with the PTGS1 gene may affect response to aspirin therapy.
Advantages:
By determining PTGS1 gene variants with genetic tests, the response of patients to aspirin can be better understood.
Correct dosage adjustments can be made, thus increasing the effectiveness of the treatment and reducing side effects.
Allowing patients to receive more personalized pain management.
Relationship between Alfentanil and OPRM1 Gene:
Alfentanil is an opioid analgesic drug used for anesthesia in surgery.
A genetic variant associated with the OPRM1 gene may increase the effectiveness of opioids for pain and opioid-related drugs to treat addiction.
Advantages:
Based on OPRM1 gene variants, patients' response and tolerance to opioids can be determined.
Correct opioid selection and dosage adjustment can be made so that pain can be effectively controlled.
A safer and more effective pain treatment is provided to reduce side effects and manage the risk of addiction.
Oncology:
Relationship between Mercaptopurine and NUDT15 Gene:
The metabolism of thiopurine drugs such as mercaptopurine has been linked to genetic variations in patients. Certain alleles in the NUDT15 gene have been associated with a reduced risk of leukopenia, neutropenia, or alopecia in patients treated with thiopurines. This may help reduce treatment-related side effects and increase treatment success.
Relationship between Methotrexate and MTHFR Gene:
The effectiveness of antifolate drugs such as methotrexate has been linked to genetic variations in patients. Certain variants of the MTHFR gene may affect the response to treatment with methotrexate and may increase or decrease the risk of treatment-related toxicity. This allows to better predict the effectiveness and safety of treatment and to personalize treatment strategies.
Others:
Relationship between Ribavirin and the IFNL3 Gene:
The effectiveness of antiviral drugs such as ribavirin has been linked to genetic variations in patients. Certain alleles of the IFNL3 gene may affect the response to ribavirin treatment in patients with Hepatitis C virus (HCV) infection. This genetic information plays an important role in determining treatment options and appropriately monitoring response to treatment.
Tacrolimus and CYP3A4 Gene Relationship:
The effectiveness of immunosuppressant drugs such as tacrolimus has been linked to genetic variations in patients. Certain variants of the CYP3A4 gene may affect the dosage of tacrolimus use. This genetic information can help determine the effective dosage of the drug in patients and contribute to reducing treatment-related side effects.